Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose the following hypothesis: discontinuation of levothyroxine (LT4)
for veterans with subclinical hypothyroidism (SCH) will be feasible, acceptable, and safe and
will not negatively affect their Quality of Life (QoL). The investigators aim to 1) evaluate
the feasibility of LT4 discontinuation among veterans with SCH and determine the changes in
QoL measures, lipids, and adverse events, and 2) assess the acceptability of LT4
discontinuation among veterans with SCH and LT4 prescribing clinicians.
Phase:
Phase 4
Details
Lead Sponsor:
Central Arkansas Veterans Healthcare System VA Office of Research and Development